Radiation plus immunotherapy: a one-two punch against metastatic cancer?

NCT ID NCT02843165

Completed Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding stereotactic body radiation therapy (SBRT) to standard checkpoint immunotherapy improves tumor response in 106 people with advanced metastatic cancer. Participants received either immunotherapy alone or immunotherapy plus SBRT to one tumor site. The goal was to see if the combination leads to more tumor shrinkage and longer time without cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Checkpoint blockade immunotherapy (anti-CTLA-4 and anti-PD-1/PD-L1 antibodies) plus stereotactic body radiation therapy (SBRT)
What this could lead to: If it works, this combination could improve tumor shrinkage and delay cancer progression in people with advanced metastatic cancer.
What could go wrong: This is a phase 2 trial with only 106 participants, so results may not apply to everyone. Adding radiation to immunotherapy can increase side effects like inflammation or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Locations

UCSD Moores Cancer Center

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.